Dow Jones Sustainability Index ranks AstraZeneca among the industry leaders

Tuesday, 11 October 2011

AstraZeneca achieved its highest-ever placing in the 2011 Dow Jones Sustainability World Index (DJSI), the world’s leading independent analysis of the sustainability performance of the 2,500 largest companies globally We also retained our listing on the DJSI STOXX - European index (the top 20% of the 600 largest European companies)  for the fourth  year running (one of only four pharmaceutical companies to do so out of 14 assessed.)

  • We achieved a total score of 85% ( 81% in 2010) compared with a sector best score of 87 % (87% in 2010)
  • We gained ground in all three dimensions - economic, environmental and social
  • We increased individual scores for 14 out of 23 criteria for 2011 (compared to 8 out of 23 criteria in 2010) - Corporate Governance, Codes of Conduct – Compliance / corruption -bribery, Research & Development, Customer Relationship Management, Innovation management, Environmental reporting, Climate strategy, Labour Practice Indicators, Talent attraction & retention, Corporate citizenship, Stakeholder Engagement, Standards for suppliers, Occupational Health & Safety and Addressing Cost Burden.
  • We saw a reduction in scores in the areas of: Marketing practices, Operational eco-efficiency, Social reporting and Health outcomes contribution.

Caroline Hempstead, VP Global Corporate Affairs said:

We are delighted by our improved ranking in the DJSI, reflecting as it does our ongoing commitment to the sustainable development of our business. But we know that there will always be more to learn about how we can further improve performance. The Index is an important ‘health check’ for us both in terms of what we're doing well and where we could do better.

DJSI Graph

In total, AstraZeneca achieved its best-ever total score of 85% (81% in 2010) compared with a sector best score of 87%.

The annual index is compiled by Strategic Asset Management (SAM) in Zurich, which defines corporate sustainability as "a business approach to create long term shareholder value by embracing opportunities and managing risks."

Each year, SAM invites the world’s largest companies from 57 sectors to report on their sustainability performance. The results provide an in-depth analysis of economic, environmental and social criteria, such as corporate governance, water-related risks and stakeholder relations, with a special focus on long-term industry-specific risks and opportunities.

My-Linh Ngo, Associate Director SRI Funds, Henderson Global Investors, said:

In conducting environmental, social and governance (ESG) analysis of companies for our SRI funds, one useful consideration is its inclusion in third party SRI/CR indices such as the DJSI. Such information can give us a good sense on how that company is view by others and so can be helpful when comparing against our own thinking.

Sustainability focused investor seminar

During September 2011, we held our annual sustainability focused investor seminar. Presentations from leaders across our business are available to download.

LabTalk is AstraZeneca’s science-focused blog where you can hear from scientists, researchers and academics discussing novel ideas, research and innovation.

Collab_in_practice_THM 20 November 2014

Collaboration in practice – partnering to accelerate drug discovery

Outcomes_trials_THM 14 November 2014

Outcomes trials: the foundation of evidence-based cardiovascular medicine

AZ_IMAGE_WEB_V2 13 November 2014

Harnessing the role of RNA in gene regulation